Biogen Plunges After Alzheimer’s Blow, Analysts Downgrade

Biogen Inc. shares plunged early on Monday and analysts braced for further declines after a U.S. Food and Drug Administration advisory panel harshly judged the efficacy of the company’s experimental Alzheimer’s disease therapy, dimming prospects it will be approved by the agency.